Results 301 to 310 of about 223,964 (346)
Some of the next articles are maybe not open access.
Dermatologic Clinics, 2003
Currently, use of standard antifungal therapies can be limited because of toxicity, low efficacy rates, and drug resistance. New formulations are being prepared to improve absorption and efficacy of some of these standard therapies. Various new antifungals have demonstrated therapeutic potential.
Aditya K, Gupta, Elizabeth, Tomas
openaire +2 more sources
Currently, use of standard antifungal therapies can be limited because of toxicity, low efficacy rates, and drug resistance. New formulations are being prepared to improve absorption and efficacy of some of these standard therapies. Various new antifungals have demonstrated therapeutic potential.
Aditya K, Gupta, Elizabeth, Tomas
openaire +2 more sources
Clinical Infectious Diseases, 1992
The discovery of the antifungal activity of azole compounds represented an important therapeutic advance. Miconazole, ketoconazole, and fluconazole are currently commercially available, and itraconazole has undergone extensive clinical evaluation. Because of its limited activity and toxicity, miconazole has been replaced by newer agents.
openaire +2 more sources
The discovery of the antifungal activity of azole compounds represented an important therapeutic advance. Miconazole, ketoconazole, and fluconazole are currently commercially available, and itraconazole has undergone extensive clinical evaluation. Because of its limited activity and toxicity, miconazole has been replaced by newer agents.
openaire +2 more sources
Current Opinion in Pediatrics, 2013
In recent years there has been an evolution of a better understanding of the pharmacology and clinical indications of existing antifungal agents and also the development of new broad-spectrum triazoles and a newer class of antifungal agents, the echinocandins.
Beatriz, Larru, Theoklis E, Zaoutis
openaire +2 more sources
In recent years there has been an evolution of a better understanding of the pharmacology and clinical indications of existing antifungal agents and also the development of new broad-spectrum triazoles and a newer class of antifungal agents, the echinocandins.
Beatriz, Larru, Theoklis E, Zaoutis
openaire +2 more sources
The Indian Journal of Pediatrics, 2001
Anti-fungal agents are classified under two major headings, systematic and topical agents. Only systematic anti-fungal agents will be discussed in this chapter. Since the discovery in 1955, amphotericin B has been the cornerstone of anti-fungal treatment. It is active against most species of fungi.
W, Abuhammour, E, Habte-Gabr
openaire +2 more sources
Anti-fungal agents are classified under two major headings, systematic and topical agents. Only systematic anti-fungal agents will be discussed in this chapter. Since the discovery in 1955, amphotericin B has been the cornerstone of anti-fungal treatment. It is active against most species of fungi.
W, Abuhammour, E, Habte-Gabr
openaire +2 more sources
NEW SYNTHETIC ANTIFUNGAL AGENTS
International Journal of Dermatology, 1964New antifungal agents of the aromatic disulphide and sulphenamide type have been investigated by chemosynthesis.
F, GIALDI, R, PONCI, P, CACCIALANZA
openaire +2 more sources
2023
Fungal infections represent an increasing threat to a growing number of immune- and medically compromised patients. Fungi, like humans, are eukaryotic organisms and there are a limited number of selective targets that can be exploited for antifungal drug development.
EstefanÃa Butassi +2 more
openaire +1 more source
Fungal infections represent an increasing threat to a growing number of immune- and medically compromised patients. Fungi, like humans, are eukaryotic organisms and there are a limited number of selective targets that can be exploited for antifungal drug development.
EstefanÃa Butassi +2 more
openaire +1 more source
Investigational Antifungal Agents
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001Several new antifungal agents, including novel compounds in familiar classes and entirely new classes targeting previously untapped mechanisms, are in various stages of the drug development process. Many new triazole antifungal agents are being studied, including voriconazole, posaconazole, and ravuconazole.
openaire +2 more sources
Obstetrics and Gynecology Clinics of North America, 1992
Current knowledge of fungal cell architecture and biochemistry allows limited understanding of the mode of action of presently available topical antifungal agents. Nystatin, first introduced in the 1950s for treatment of vulvovaginal candidiasis, has been surpassed by the imidazoles and triazoles as the first choice of treatment for vulvovaginal ...
openaire +2 more sources
Current knowledge of fungal cell architecture and biochemistry allows limited understanding of the mode of action of presently available topical antifungal agents. Nystatin, first introduced in the 1950s for treatment of vulvovaginal candidiasis, has been surpassed by the imidazoles and triazoles as the first choice of treatment for vulvovaginal ...
openaire +2 more sources
Expert Review of Anti-infective Therapy, 2011
The frequency and spectrum of fungal infections have been increasing steadily over the last several decades. The reason for this increase may be explained by the increase in the number of immunocompromised patients due to malignancies, AIDS, invasive surgical procedures and transplantation.
openaire +2 more sources
The frequency and spectrum of fungal infections have been increasing steadily over the last several decades. The reason for this increase may be explained by the increase in the number of immunocompromised patients due to malignancies, AIDS, invasive surgical procedures and transplantation.
openaire +2 more sources
Clinical Microbiology Newsletter, 1982
For more than two decades, amphotericin B has been the single broad-spectrum agent for the treatment of systemic mycoses. Amphotericin B is not always effective, must be given parenterally, and is associated with a host of adverse reactions. Despite amphotericin B toxicity, until recently the systemic mycoses did not rate enough attention to prompt a ...
openaire +2 more sources
For more than two decades, amphotericin B has been the single broad-spectrum agent for the treatment of systemic mycoses. Amphotericin B is not always effective, must be given parenterally, and is associated with a host of adverse reactions. Despite amphotericin B toxicity, until recently the systemic mycoses did not rate enough attention to prompt a ...
openaire +2 more sources